Active Ingredients: PembrolizumabStrength: 100 mg/4 mL (25 mg/mL)Dosage Form: Syringe, VialMechanism of Action: PD-1 ligands antagonistsFirst Approval: US (Sep 4, 2014), EU (Jul 17, 2015)RevenueKeytruda (pembrolizumab) has been a key player in Merck & Co. immuno-oncology drugs for the past years – reaching nearly $17B in annual sales in 2021. Despite the dampening impact…